chrisvoncsefalvay/vaers-outcomes huggingface dataset:
On  January 16, the day after being vaccinated (1/15/21),  I woke up with my arms, hands, legs and feet tingling and numb all over and it lasted on and off all day January 16 and on and off all day January 17 and has persisted every day until Monday, January 26 when the symptoms became worse. Instead of tingling in all extremities (with some numbness)  the sensations changed to a pins and needles sensation with burning and random electrical shock sensations. I want to note that, yes, I have radiculopathies  - however, I have never had them change so suddenly and increase in intensity so fast. Also, the pins and needles sensation with burning and random electrical shocks are brand new symptoms for me (my radiculopathies have not presented this way before).  I reported these symptoms to my primary care provider today (1/29/21) and she instructed me to report my symptoms to VAERS and she is referring me to neurology. Note: I received my vaccination outside of my health care system and received it through the county because I could get the vaccination sooner that way.  I did not report these symptoms sooner because they were not listed as a possible adverse effect of getting the COVID19 Moderna  vaccination. However, as these symptoms have worsened over the past 2 weeks I have become concerned.  I have not added any OTC medications or supplements to the ones listed prior. I have gone to a chiropractor twice during this time for relief of my back pain with  no positive outcomes. Waiting to see the neurologist.
Patient stated she experienced 2 weeks of vaginal bleeding after receiving the vaccine and accompanied with this was 1.5 weeks of extremely intense cramps.
Breakthrough COVID-19 case with symptom onset 9/1/2021: Fever, Aches, Runny Nose/Congestion, Sore Throat, Shortness of breath/difficulty breathing, Nausea/Vomiting, Loss of smell or taste, Fatigue or tiredness, Chills, Cough. Hospitalized on 9/1/2021 with pneumonia due to COVID-19 and hyperglycemia for unknown duration. Pt was admitted to the ICU for tx of Covid pneumonia and hyperglycemia and acute on chronic kidney injury. Pt was placed in the ICU on an insulin drip and fluids and oxygen. Pt does not have good control of glucose levels. Pt was not hypoxic.
Patient describe severe pain in arm where received injection.  She could lift her arm but not above shoulder and is very painful.  She went to the doctor, her arm was swollen and the pain radiated up to the neck.  She was prescribed hydrocodone for the pain.
This spontaneous report as received from a nurse refers to a 2 year old patient of unknown gender. The patient's relevant medical history, concurrent conditions, concomitant medications, drug reactions or allergies were not reported. On 12-SEP-2017, the patient was vaccinated with improperly stored VAQTA (dosing details were not reported) (lot # N008823, expiry date: 26-MAY-2018) for prophylaxis. No adverse effects were reported. Temperature excursion was from 0 degree Celsius (C) to 1 degree C (0.8 degree C) for 52 minutes. The previous temperature excursion was reported as 9 degree C to 25 degree C (10.9 degree C) for 3 hours 17 minutes. The call was because of a data logger. No product quality complaint involved. This is one of several reports received from the same reporter. Sender's Comments: US-009507513-1709USA007011: US-009507513-1709USA007012: US-009507513-1709USA007013: US-009507513-1709USA007014: US-009507513-1709USA000054.
1/7/21 - ALL joiNTS WORse PAiN FeVER 99.1 1/8-1/9/21 - Swelling with edema in both Legs
This spontaneous report as received from a medical assistant refers to a patient of unknown age. The patient was vaccinated with dose 1, .5 ml GARDASIL on 19-APR-2012 and with dose 2 on 15-NOV-2012. No adverse event was reported. No other co-suspects were reported. No concomitant medications were reported. Additional information has been requested.
severe body pain (headache, neck, lumbosacral, bilat arms, bilat calves, bilat legs. chills.
chills; my entire body was shaking; my body ached; headache; worn out; Booster; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non-HCP). The reporter is the patient.  A 52-year-old male patient received bnt162b2 (BNT162B2), administered in arm left, administration date 07Dec2021 10:00 (Lot number: 33130BA) at the age of 52 years as dose 3 (booster), single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose Number: 1, Batch/Lot No: EK9231, Location of injection: Arm Left, Vaccine Administration Time: 02:00 PM), administration date: 09Jan2021, when the patient was 51 years old, for COVID-19 Immunisation, reaction(s): "No side effects"; Bnt162b2 (Dose Number: 2, Batch/Lot No: EL3247, Location of injection: Arm Left, Vaccine Administration Time: 05:00 PM), administration date: 30Jan2021, when the patient was 51 years old, for Covid-19 Immunisation, reaction(s): "minor chills"; Bnt162b2 (Dose Number: 2, Batch/Lot No: EL3247, Location of injection: Arm Left, Vaccine Administration Time: 05:00 PM), administration date: 30Jan2021, when the patient was 51 years old, for COVID-19 Immunization, reaction(s): "body ache", "headache". The following information was reported: IMMUNISATION (non-serious) with onset 07Dec2021 10:00, outcome "unknown", described as "Booster"; CHILLS (non-serious) with onset 07Dec2021 20:00, outcome "recovered" (2021), described as "chills"; TREMOR (non-serious) with onset 07Dec2021 20:00, outcome "recovered" (2021), described as "my entire body was shaking"; PAIN (non-serious) with onset 07Dec2021 20:00, outcome "recovered" (2021), described as "my body ached"; HEADACHE (non-serious) with onset 07Dec2021 20:00, outcome "recovered" (2021), described as "headache"; FATIGUE (non-serious) with onset 07Dec2021 20:00, outcome "recovered" (2021), described as "worn out". Therapeutic measures were not taken as a result of chills, tremor, pain, headache, fatigue.  Additional Information: The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient did not receive any other vaccines within 2 weeks of vaccination. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19. It was reported that 10-hours after the 3rd vaccination patient began to get the chills. He had the chills so bad entire body was shaking and body ached. Had a headache. This lasted for another 6 hours, and then just had minor chills. Patient was slept for 10 hours and woke up feeling better, but patient did not have minor chills and patient was just worn out. After another 8 hours he finally lost the chills and was pretty much back to normal but was just worn out. That was the sick-est patient have ever been in his life. Patient had minor chills and body ache that lasted about 12 hours and a headache that lasted for 4 days after the 2nd dose. No side effects from the first vaccine.   No follow-up attempts are possible. No further information is expected.
Information has been received from a registered nurse concerning a patient who on 01-MAR-2000 was vaccinated with a dose of Varivax. Subsequently, on 18-MAR-2006, the patient developed breakthrough varicella. Unspecified medical attention was sought. There was no product quality complaint. No additional information is expected.
Sweating; Backache; Vomiting; Chills; Fatigue; Diarrhea; This spontaneous case was reported by a consumer and describes the occurrence of DIARRHOEA (Diarrhea), HYPERHIDROSIS (Sweating), BACK PAIN (Backache), FATIGUE (Fatigue) and VOMITING (Vomiting) in a 74-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history was reported.     On 12-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 12-Feb-2021, the patient experienced DIARRHOEA (Diarrhea) and FATIGUE (Fatigue). On 01-Mar-2021, the patient experienced HYPERHIDROSIS (Sweating), BACK PAIN (Backache), VOMITING (Vomiting) and CHILLS (Chills). On 02-Mar-2021, DIARRHOEA (Diarrhea), HYPERHIDROSIS (Sweating), BACK PAIN (Backache), FATIGUE (Fatigue), VOMITING (Vomiting) and CHILLS (Chills) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment information was provided. Wife is called on behalf of husband. He had the vaccine on 12 Feb 2021. He has had diarrhea, fatigue on and off for the past couple weeks. On 1 Mar 2021, he was vomiting, had diarrhea, was sweating, with chills, and a backache. He is feeling better today.
DIED WITHIN 5 DAYS OF RECEIEVING THE 2ND DOSE, EXPERIENCED GENERALIZED WEAKNESS.
SUNBURN-LOOKING SPOT (UNDERNEATH LEFT ARM & LEFT BREAST); WARM TO TOUCH; This spontaneous report received from a patient concerned a 62 year old female. The patient's height, and weight were not reported. The patient's concurrent conditions included non alcohol, and non smoker. The patient experienced drug allergy when treated with diphenhydramine hydrochloride, and dextropropoxyphene hydrochloride.  The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, intramuscular, batch number: 1805025, expiry: UNKNOWN) dose was not reported, administered on 08-MAR-2021 00:30 to Left Arm for prophylactic vaccination. No concomitant medications were reported.  On 13-MAR-2021, the subject experienced sunburn-looking spot (underneath left arm & left breast). On 13-MAR-2021, the subject experienced warm to touch. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from sunburn-looking spot (underneath left arm & left breast), and warm to touch. This report was non-serious.
PATIENT HAD COVID-19 VACCINE ON Dose 1 date: 12/23/2020,    Dose 2 date: 01/12/2021, AND TESTED POSITIVE TO COVID.
Information has been received from a physician concerning a white, 75 yr old, retired female, whose reported weight was 131 pounds with allergies to penicillin, naproxen sodium (Aleve) and Neosporin who on 01Nov05 was vaccinated SC with a 0.5cc dose of pneumococcal 23v polysaccharide vaccine (lot 650082/0691P). The physician reported that this was the pt's 3rd vaccination of pneumococcal 23v polysaccharide vaccine following an every 5 yr pattern. The pt was seen by the physician on 23Jan06. The pt reported to the physician that after receiving the pneumococcal 23v polysaccharide vaccination, she began to experience for 1 wk a sore, swollen arm and was very nauseated. The physician stated the following about the pt being the stoic individual she is, she sought no medical attention and took no treatment. The physician reported that the pt had recovered 1 wk later, after receiving  the pneumococcal 23v polysaccharide vaccination without incident. The pt was advised to no longer receive the pneumococcal 23v polysaccharide vaccine. Additional information is not expected.
This spontaneous report was received from a pharmacist and refers to a patient of unknown age and gender. No information about the patient's pertinent medical history, concomitant medications, drug reactions or allergies was provided. On 16-APR-2016, the patient was vaccinated with an improperly stored dose of ZOSTAVAX lot # L034724, expiration date 09-DEC-2016 (dose and route of administration were not reported). No adverse effects reported. This is one of several reports received from the same source. Additional information has been requested.
This medically confirmed spontaneous report (initial receipt 12-OCT-2010) concerns a 32-year-old female. On 11-OCT-2010 10:30, the patient received AFLURIA (Lot# M51908) at a dose of 0.5 cc intramuscularly for immunization. On 11-OCT-2010 11:00, thirty minutes after AFLURIA was administered, the patient developed inflammation around the injection site. The site was red, swollen and painful. The area was warm to the touch. On 14-OCT-2010, the patient was considered to have recovered from the events. The reporter considered events non serious. Follow up 1 (07-DEC-2010): additional adverse events, event outcome, listedness changed to unlisted, narrative added.
On about 4/24/2022, I developed a cough and runny nose. I took a home antigen test on 4/25/2022 and got a positive result. On 4/26/2023, I went to a clinic at a pharmacy and underwent a rapid test, which confirmed the positive result of the home test. I was prescribed Paxlovid, which I began taking 4/26/2022. The medication left a nasty, metallic aftertaste in my mouth, but aside from that, I had no other side effects. Within 24 hours of beginning the Paxlovid, I began to feel better. I finished the five-day course of Paxlovid, and I tested negative on 5/6/2022. I followed the CDC protocols for self-isolation during this time. On 6/13/2022, I had a cough and runny nose, At 3:46 PM on that day, I took a home antigen test and got a positive result. I called my NP and had a telehealth visit with him. Because of the timing of the illness, I asked him if it could be a rebound case. He didn't think it was a rebound, but he also decided not to prescribe me Paxlovid, because at that time, there was no guidance regarding prescribing it so soon after having already prescribed it. At this time, there was a new omicron subvariant of COVID-19, and my NP thought that this may have been the reason why I caught COVID-19 again so quickly after having gotten it the first time. However, he didn't run any tests to determine the strain that I had. Again, I followed the CDC protocols for self-isolation, and I felt better a few days after the onset of symptoms. On 6/23/2022, I took a home antigen test and got a negative result.
Large localized reaction to Dtap given 7/27/2020. Photos scanned into chart. Redness and swelling mild at hour 28. Became severe with blisters by hour 36. No fever.
Pt recv vax on 10/7/98; on 10/8/98 pt exp fever (102F)& seizure
some nose bleeding; nasal congestion; having on and off chills for 1 week; This spontaneous case was reported by a consumer and describes the occurrence of EPISTAXIS (some nose bleeding), NASAL CONGESTION (nasal congestion) and CHILLS (having on and off chills for 1 week) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced EPISTAXIS (some nose bleeding), NASAL CONGESTION (nasal congestion) and CHILLS (having on and off chills for 1 week). At the time of the report, EPISTAXIS (some nose bleeding), NASAL CONGESTION (nasal congestion) and CHILLS (having on and off chills for 1 week) outcome was unknown.            No Concomitant medication was provided.  No Treatment medications was provided.   Reporter did not allow further contact
No adverse event; Dose 1 and Dose 2 taken on 22-Jul-22 and 2-Sep-22, 42 days apart; This spontaneous case was reported by an other health care professional and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Dose 1 and Dose 2 taken on 22-Jul-22 and 2-Sep-22, 42 days apart) and NO ADVERSE EVENT (No adverse event) in a 4-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. AR9237B and AS1412B) for COVID-19 prophylaxis.     No Medical History information was reported.   On 22-Jul-2022, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 25 microgram. On 02-Sep-2022, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 25 microgram. On 02-Sep-2022, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Dose 1 and Dose 2 taken on 22-Jul-22 and 2-Sep-22, 42 days apart). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Dose 1 and Dose 2 taken on 22-Jul-22 and 2-Sep-22, 42 days apart) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Dose 1 and Dose 2 taken on 22-Jul-22 and 2-Sep-22, 42 days apart).    Concomitant product use was not provided by the reporter.  Treatment information was not provided.   This case was linked to MOD-2023-697101 (Patient Link).
Patient was dizzy and light headed after getting the vaccine.  Patient stated he had not had anything to eat all day.  After drinking water and eating some chips patient stated he was fine.
Headaches and fatigue onset the night after the injection, and have persisted through today. The morning after receiving the injection, I had a migraine, nausea, fatigue, severe muscle aches, and fever/chills. All symptoms except headache and fatigue resolved by the next morning.
I was shaky and dizzy; I was shaky and dizzy; I was exhausted," very fatigued; She took first dose of the vaccine and she had a very weird and fairly dramatic side effect; I felt high or drunk like I had had 5 drinks; I felt high or drunk like I had had 5 drinks; This is a spontaneous report from a contactable consumer (patient) via Medical information team. A 62-years-old female patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: Solution for injection, Lot Number: Unknown) via an unspecified route of administration on an unspecified date as single dose for covid-19 immunisation. The patient medical history and concomitant medications were not reported. On an unspecified date, the patient felt high or drunk like had 5 drinks, shaky and dizzy, exhausted, very fatigued. The clinical course of the events included: patient reported that she had her 1st Pfizer vaccine a couple weeks ago and she was due to get the 2nd vaccine dose next week. Her height reported 5 feet and 95 and tiny person. Patient was hesitant to receive 2nd dose because of her side effects with the first vaccine dose. Caller stated that 1 to 1.5 hours after she got her shot, she felt high or drunk like she had 5 drinks, she was shaky and dizzy. This went on for 3 hours then she was exhausted, very fatigued for the rest of the day. After vaccination, she had a very weird and fairly dramatic side effect. Her doctors did not know whether she should get the second dose. Advised her to consult with other healthcare professional and informed they are unable to provide medical advice. Outcome of the events was unknown.  Information on the Lot/batch number has been requested.   Follow-up attempts are completed. No further information is expected.
1st dose 2020, 2nd not yet; This case was reported by a other health professional via sales rep and described the occurrence of incomplete course of vaccination in a patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received 1st dose in 2020).   On an unknown date, the patient did not receive the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown.   Additional Information: GSK receipt date: 25-OCT-2022 Reporter's comment:  The reporter reported that they have a patient that was not received the 2nd dose of Shingrix since 2020.  The reporter was consented to follow up. Additional Supportive Information:  Till the time of reporting the patient did not receive 2nd dose of vaccine, which led to incomplete course of vaccination.
Red, flat maculopapular rash on trunk and extremities sparing the head. Mild fever. Runny nose.
Blood clot in lower right leg (calf), resulting in pulmonary embolisms and use of blood thinners.  Due to fibroids, this caused excessive bleeding leading to anemic condition and the need for several blood and iron transfusions.  Solution was to perform hysterectomy to eliminate fibroids and bleeding to be able to continue use of blood thinners for blood clot condition.
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 39-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 01Apr2021 as dose 1, single (Batch/Lot number: unknown), in left arm, on 28Apr2022 as dose 2, single (Batch/Lot number: unknown), in left arm and on 17Jun2022 as dose 3 (booster), single (Batch/Lot number: unknown) at the age of 38 years, in left arm for covid-19 immunisation. The patient had no relevant medical history. The patient has no known allergies. There were no concomitant medications. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "Treatment of COVID-19". Therapeutic measures were taken as a result of drug ineffective, COVID-19 and included Paxlovid. Clinical course: Anti-viral details: COVID-19 Treatment (Paxlovid) was started from 10Aug2022 and stopped on 14Aug2022.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
This spontaneous report was received from a physician via company representatives referring to a patient of unknown age and gender. The patient's concurrent conditions and medical history were not provided. On 04-NOV-2014, the patient was vaccinated with an improperly stored dose of PNEUMOVAX 0.5 mL (Vls 10 SDV) (Lot # K007822, expiration date 15-AUG-2015) single dose, route and anatomical location were not provided. There was no concomitant medication provided. No adverse effects were reported. On an unknown date, the PNEUMOVAX had a temperature excursion for 804 hours, the lowest recorded temperature was 20F (-6.667 Celsius). The vaccine status was reported as "in excursion", the storage criteria and the vaccine excursion were reported as "Refrigerator (R)". There was no product quality complaint involved. This is one of several cases received from the same reporter. Additional information has been requested.
Mild to moderate "cold symtoms". Took Rimantadine 100 mg bid. Residual dry cough and "sensation" of shortness of breath at rest. Able to exercise 5 K walking daily as before.
Got shot, fine for 2 days, then left arm started to ache. Kept increasing in pain. No pain killer touched pain. Put on NEURONTIN after building up of 2 wks or so finally dealt with pain. Was on NEURONTIN for 6 mos. According to Dr shot hit nerve developed shingles without rash on arm. I also developed sores across my shoulders which happened before number of years ago.
Patient admitted as observation on 11/1 due to pneumonia due to COVID-19 virus. Patient was tested for COVID-19 and was positive on 11/1. Symptoms started about a week ago. Also endorses cough. Was covid positive in ER today. Notes some leg swelling which is not a new issue for him. Denies chest pain. In the ER bnp elevated, CXR c/w pulmonary edema vs atypical infection. EKG without acute ischemic changes. Mild hypoglycemia. Afebrile. Not hypoxic but was tachypneic and reportedly some desaturation w/ activity. He is on warfarin. Prior hx of what cardiology is calling likely nonischemic cardiomyopathy thought to be tachycardia induced. Per notes prior cath showed LAD lesion but no intervention done at that time. See ulm for asthma, on breo at home.
Hep B dose 1: pt had mild sore throat and slightly swollen uvula. 11-16-05 pt. received dose #2. 11-18-05 patient awoke with a uvula so swollen he could barely talk. Was seen at 9 AM. No fever, strep test was neg. Dr. told mother that it could be a rare reaction to the Hep B immunization and advised not to get dose #3. Dr. will order a titer.